Physician profile
James W Bedsole
NPI 1700879145
$5,489.92
in general payments reported to CMS, 2019-2025
20 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $162 · 2021: $503 · 2022: $335 · 2023: $1,454 · 2024: $1,419 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,062 · Entertainment: $33.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,061.70 |
| Entertainment | $33.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,373.48 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $803.42 | 2020-2025 | Precision 1, Precision7, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $707.44 | 2021-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $335.70 | 2019-2025 | |
| Abbvie INC. | $325.98 | 2023-2025 | Vuity, Lumigan, Alphagan P |
| Eyevance Pharmaceuticals LLC | $277.13 | 2021-2022 | |
| Astellas Pharma US INC | $261.41 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $246.74 | 2023 | Acthar |
| Optos, INC. | $166.66 | 2020-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $159.78 | 2019-2022 | |
| Coopervision INC. | $149.10 | 2019-2023 | Myday Contact Lens |
| Biotissue Holdings INC. | $146.65 | 2023-2024 | |
| Carl Zeiss Meditec USA, INC. | $138.42 | 2025 | Cirrus Hd-Oct |
| Johnson & Johnson Surgical Vision, INC. | $118.80 | 2019 | |
| Glaukos Corporation | $111.20 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.93 | 2023 | |
| Dompe US, INC. | $25.79 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $21.37 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $13.17 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bedsole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.